Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908722 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,609
- Enrollment target
NCT04908722: Completed Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
NCT04908722 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 1,609 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (108% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04908722, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,609 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
Primary Outcome
Geometric mean concentration of SARS-CoV-2 S protein binding antibodies measured by ELISA were reported. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study.
Interventions
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,609 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 3 |
What the finished NCT04908722 record still lists
NCT04908722 is an interventional study that assigns participants to a tested intervention. Its 1,609 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (108% higher).
The record links to 0 conditions, and to 1 intervention - of which Ad26.COV2.S is the first listed.
NCT04908722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04908722 about?
NCT04908722 is a clinical study titled "A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults". The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
What is the current status of trial NCT04908722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,609 participants. The study started on 2021-06-18. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT04908722?
The interventions under investigation include: Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04908722?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04908722's enrollment target sits among peer trials
1,609 142nd of 2000 higher than 1,859 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI